Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tergenpumatucel-L in advanced NSCLC
NCT00420732Phase 2Terminated
- Sponsor
- Lumos Pharma, Inc.
- Start
- Jan 2007
- Primary completion
- Nov 2012
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of tergenpumatucel-l in non-small cell lung cancer (NSCLC), sponsored by Lumos Pharma, Inc.. Started Jan 2007; status: terminated.
02
Drugs
tergenpumatucel-l
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00420732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00420732.